Cargando…

Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System

BACKGROUND: A new category system comprising five classes (C1-insufficient material, C2-benign, C3-atypical, C4-suspicious, and C5-malignant) has been proposed by the International Academy of Cytology (IAC) for fine needle aspiration biopsy cytology (FNAB) for proper diagnosis of breast cancer. AIMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Niaz, Mahwish, Khan, Azmat Ali, Ahmed, Safina, Rafi, Rabia, Salim, Hassan, Khalid, Kashaf, Kazi, Faiza, Anjum, Awais, Waheed, Yasir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093610/
https://www.ncbi.nlm.nih.gov/pubmed/35573260
http://dx.doi.org/10.2147/CMAR.S362155
_version_ 1784705369216385024
author Niaz, Mahwish
Khan, Azmat Ali
Ahmed, Safina
Rafi, Rabia
Salim, Hassan
Khalid, Kashaf
Kazi, Faiza
Anjum, Awais
Waheed, Yasir
author_facet Niaz, Mahwish
Khan, Azmat Ali
Ahmed, Safina
Rafi, Rabia
Salim, Hassan
Khalid, Kashaf
Kazi, Faiza
Anjum, Awais
Waheed, Yasir
author_sort Niaz, Mahwish
collection PubMed
description BACKGROUND: A new category system comprising five classes (C1-insufficient material, C2-benign, C3-atypical, C4-suspicious, and C5-malignant) has been proposed by the International Academy of Cytology (IAC) for fine needle aspiration biopsy cytology (FNAB) for proper diagnosis of breast cancer. AIMS AND OBJECTIVES: This study is designed to categorize institutional FNAB data according to the new system and calculation of the absolute risk of malignancy (ROM), sensitivity, specificity, positive predictive values, false negative and false-positive rate. STUDY DESIGN: We conducted a retrospective cross-sectional study involving 2133 cases collected between June, 2008 and August, 2019, at Foundation University Medical College’s Department of Histopathology and the Surgery and Oncology Department at the Fauji Foundation Hospital. All cases fulfilling the inclusion and exclusion criteria were retrieved from the archives and reviewed by two expert pathologists. Matching histopathology was compared with the cytology reports for concordance or discordance of results. FINDINGS: We found 6.9% (n = 147) insufficient, 65.8% (n = 1403) benign, 7.2% (n = 153) atypical, 7.5% (n = 160) suspicious and 12.6% (n = 270) malignant cases. Cyto-histological correlation was found in 421 cases from the year 2014 to 2019 with 370 concordant and 51 discordant cases. The maximum number of concordant cases was 151 in the C5 category and discordant cases had a diagnosis of C3 and C4 on cytology with 16 cases in each category. The calculated values of ROM were 45.45%, 10.3%, 30.6%, 82.79% and 99.34% from C1 to C5, respectively. We calculated 83.42% absolute sensitivity and 85.24% specificity. The positive predictive value for category 3, 4 and 5 was 67.34%, 82.7% and 99.34%, respectively, while false-negative rate was 7.9% and false-positive rate was 0.66%. CONCLUSION: The ROM for C1 category calculated from this study is quite high (45.45%) compared to previous studies; therefore, it is recommended to perform core needle biopsy in all these cases. The higher sensitivity and specificity of this method of diagnosing malignant lesions supports its use.
format Online
Article
Text
id pubmed-9093610
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90936102022-05-12 Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System Niaz, Mahwish Khan, Azmat Ali Ahmed, Safina Rafi, Rabia Salim, Hassan Khalid, Kashaf Kazi, Faiza Anjum, Awais Waheed, Yasir Cancer Manag Res Original Research BACKGROUND: A new category system comprising five classes (C1-insufficient material, C2-benign, C3-atypical, C4-suspicious, and C5-malignant) has been proposed by the International Academy of Cytology (IAC) for fine needle aspiration biopsy cytology (FNAB) for proper diagnosis of breast cancer. AIMS AND OBJECTIVES: This study is designed to categorize institutional FNAB data according to the new system and calculation of the absolute risk of malignancy (ROM), sensitivity, specificity, positive predictive values, false negative and false-positive rate. STUDY DESIGN: We conducted a retrospective cross-sectional study involving 2133 cases collected between June, 2008 and August, 2019, at Foundation University Medical College’s Department of Histopathology and the Surgery and Oncology Department at the Fauji Foundation Hospital. All cases fulfilling the inclusion and exclusion criteria were retrieved from the archives and reviewed by two expert pathologists. Matching histopathology was compared with the cytology reports for concordance or discordance of results. FINDINGS: We found 6.9% (n = 147) insufficient, 65.8% (n = 1403) benign, 7.2% (n = 153) atypical, 7.5% (n = 160) suspicious and 12.6% (n = 270) malignant cases. Cyto-histological correlation was found in 421 cases from the year 2014 to 2019 with 370 concordant and 51 discordant cases. The maximum number of concordant cases was 151 in the C5 category and discordant cases had a diagnosis of C3 and C4 on cytology with 16 cases in each category. The calculated values of ROM were 45.45%, 10.3%, 30.6%, 82.79% and 99.34% from C1 to C5, respectively. We calculated 83.42% absolute sensitivity and 85.24% specificity. The positive predictive value for category 3, 4 and 5 was 67.34%, 82.7% and 99.34%, respectively, while false-negative rate was 7.9% and false-positive rate was 0.66%. CONCLUSION: The ROM for C1 category calculated from this study is quite high (45.45%) compared to previous studies; therefore, it is recommended to perform core needle biopsy in all these cases. The higher sensitivity and specificity of this method of diagnosing malignant lesions supports its use. Dove 2022-05-07 /pmc/articles/PMC9093610/ /pubmed/35573260 http://dx.doi.org/10.2147/CMAR.S362155 Text en © 2022 Niaz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Niaz, Mahwish
Khan, Azmat Ali
Ahmed, Safina
Rafi, Rabia
Salim, Hassan
Khalid, Kashaf
Kazi, Faiza
Anjum, Awais
Waheed, Yasir
Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title_full Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title_fullStr Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title_full_unstemmed Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title_short Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System
title_sort risk of malignancy in breast fnab categories, classified according to the newly proposed international academy of cytology (iac) yokohama system
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9093610/
https://www.ncbi.nlm.nih.gov/pubmed/35573260
http://dx.doi.org/10.2147/CMAR.S362155
work_keys_str_mv AT niazmahwish riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT khanazmatali riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT ahmedsafina riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT rafirabia riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT salimhassan riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT khalidkashaf riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT kazifaiza riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT anjumawais riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem
AT waheedyasir riskofmalignancyinbreastfnabcategoriesclassifiedaccordingtothenewlyproposedinternationalacademyofcytologyiacyokohamasystem